NCT01147536 2021-06-03
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Agenus Inc.
Phase 2 Terminated
Agenus Inc.
Agenus Inc.
Agenus Inc.
Agenus Inc.